**Title:** High-flow nasal cannula vs non-invasive ventilation in acute hypoxia: Propensity score matched study

**Authors**: Elizabeth S Munroe, MD, MSc<sup>1</sup>, Ina Prevalska, MD<sup>2</sup>, Madison Hyer, MS,<sup>3</sup> William J Meurer, MD, MS<sup>2</sup>, Jarrod M Mosier, MD<sup>4,5</sup>, Mark A. Tidswell, MD<sup>6</sup>, Hallie C Prescott, MD, MSc<sup>1,7</sup> Lai Wei, PhD, MS<sup>3</sup>, Henry Wang, MD, MPH, MP<sup>8</sup>, Christopher M Fung, MD MS<sup>2</sup>

- 1- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan
- 2- Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan
- 3- Center for Biostatistics, The Ohio State University, Columbus, OH
- 4- Department of Emergency Medicine, University of Arizona College of Medicine, Tucson, Arizona
- 5- Division of Pulmonary, Allergy, Critical Care and Sleep, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona
- 6- Division of Pulmonary and Critical Care, Department of Medicine, University of Massachusetts Chan Medical School – Baystate Medical Center, Springfield, MA
- 7- VA Center for Clinical Management Research, Ann Arbor, Michigan
- 8- Department of Emergency Medicine, The Ohio State University, Columbus, OH

#### **Correspondence:**

Elizabeth S Munroe, MD, MSc 6301 Medical Science Research Building III, SPC 5642 Ann Arbor, MI 48109-5360 Phone: (734) 763-2246 Email: munroeel@med.umich.edu

#### Word counts

Text: 3,076 Abstract: 250 Figures/Tables: 5 This paper has an online supplement.

Running title: Comparison of non-invasive respiratory support

Descriptor: 4.13 Ventilation: Non-Invasive/Long-Term/Weaning

Conflicts of Interest: JMM has received travel support from Fisher & Paykel.

**Funding:** Author ESM was supported by Grant Number T32 HL 007749 (Multidisciplinary Training Program in Lung Disease) and Grant Number L30 HL 170379 (Loan Repayment Award) from the National Institutes of Health. This work was supported in part by a grant from NIH (NINDS and NHLBI) for infrastructure for the Clinical Coordinating Center for the Strategies to Innovate EmeRgENcy (SIREN) Care

It is made available under a CC-BY-NC-ND 4.0 International license .

Clinical Trials Network- 2U24NS100659. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This manuscript does not represent the views of the Department of Veterans Affairs or the US government.

**Authors' contributions:** ESM, IP, and CMF contributed to the conceptualization and design of the study, data analysis and interpretation, and drafting of this manuscript. MH, WJM, JMM, MAT, WL, HW contributed to the conceptualization of the study, data interpretation, and the writing of the manuscript, including substantive revisions. HCP contributed to data interpretation and the writing of the manuscript, including substantive revisions. All authors have read and approved the final manuscript.

**Impact**: In this propensity score matched retrospective study of patients with early acute hypoxemic respiratory failure, initial treatment with non-invasive ventilation was superior to high-flow nasal cannula for major adverse pulmonary events, calculated using a Win Ratio. These results underscore the need for novel randomized controlled trials to definitively determine the merits of each non-invasive respiratory support strategy.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 1 Abstract

### 2 RATIONALE

- 3 The optimal treatment for early hypoxemic respiratory failure is unclear, and both high-
- 4 flow nasal cannula and non-invasive ventilation are used. Determining clinically relevant
- 5 outcomes for evaluating non-invasive respiratory support modalities remains a
- 6 challenge.
- 7

### 8 OBJECTIVES

- 9 To compare the effectiveness of initial treatment with high-flow nasal cannula versus
- 10 non-invasive ventilation for acute hypoxemic respiratory failure.

#### 11 METHODS

- 12 We conducted a retrospective cohort study of patients with acute hypoxemic respiratory
- 13 failure treated with high-flow nasal cannula or non-invasive ventilation within 24 hours of
- 14 Emergency Department arrival (1/2018-12/2022). We matched patients 1:1 using a
- 15 propensity score for odds of receiving non-invasive ventilation. The primary outcome
- 16 was major adverse pulmonary events (28-day mortality, ventilator-free days, non-
- 17 invasive respiratory support hours) calculated using a Win Ratio.

#### 18 MEASUREMENTS AND MAIN RESULTS

- 19 1,265 patients met inclusion criteria. 795 (62.8%) received high-flow oxygen and 470
- 20 (37.2%) received non-invasive ventilation. We propensity score matched 736/1,265
- 21 (58.2%) patients. There was no difference between non-invasive ventilation vs high-flow

It is made available under a CC-BY-NC-ND 4.0 International license .

- nasal cannula in 28-day mortality (17.7% vs 23.1%, p=0.08) or ventilator-free days
- 23 (median [Interquartile Range]: 28 [25, 28] vs 28 [13, 28], p=0.50), but patients on non-
- 24 invasive ventilation required treatment for fewer hours (median 7 vs 13, p< 0.001). Win
- 25 Ratio for composite major adverse pulmonary events favored non-invasive ventilation
- 26 (1.26, 95%CI 1.06-1.49, p< 0.001).

## 27 CONCLUSIONS

- 28 In this observational study of patients with acute hypoxemic respiratory failure, initial
- 29 treatment with non-invasive ventilation was superior to high-flow nasal cannula for major
- 30 pulmonary adverse events. Evaluation of composite outcomes is important in the
- 31 assessment of respiratory support modalities.
- 32
- 33 Abstract word count: 250/250
- 34
- 35 Key words: acute hypoxemic respiratory failure, non-invasive ventilation, oxygen
- 36 inhalation therapy

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 37 Introduction

Acute hypoxemic respiratory failure is a major cause of hospitalizations in the US.<sup>1,2</sup> 38 There is growing evidence that non-invasive respiratory support may help prevent 39 invasive mechanical ventilation in patients with respiratory failure.<sup>3</sup> Traditionally, the 40 primary mode of non-invasive respiratory support was non-invasive positive pressure 41 42 ventilation (NIV)—continuous positive airway pressure and bilevel positive airway pressure. Over the past decade, accelerated by the COVID-19 pandemic, high-flow 43 nasal canula (HFNC) has emerged as an alternative.<sup>4,5</sup> NIV and HFNC work through 44 45 different mechanisms and thus have different benefits and harms. NIV improves oxygenation by increasing mean airway pressure but has the potential to deliver 46 injurious lung volumes which may put patients at risk for patient self-induced lung 47 injury.<sup>3,6,7</sup> In contrast, HFNC provides less positive pressure ventilatory support than 48 NIV, which may decrease the risk for self-induced lung injury and can help improve 49 patient tolerance.7-10 50

51

The optimal mode of non-invasive respiratory support in acute hypoxemic respiratory 52 failure remains unclear.<sup>3,11</sup> While guidelines recommend NIV for patients with acute 53 decompensated heart failure and chronic obstructive pulmonary disease exacerbations, 54 these recommendations are based on comparisons of NIV to low-flow oxygen not 55 56 HFNC.<sup>3,11</sup> Guidelines further conclude that there is not enough evidence to make a recommendation for HFNC vs NIV in other etiologies of hypoxemic respiratory failure.<sup>3</sup> 57 The few trials that have directly compared HFNC to NIV have been limited by their focus 58 on narrow populations.<sup>4,12–15</sup> The largest trial found that for intensive care unit (ICU) 59

It is made available under a CC-BY-NC-ND 4.0 International license .

patients with pure hypoxemic respiratory failure, HFNC decreased mortality compared
to NIV.<sup>13</sup> However, trials in different populations, e.g., COVID-19 or
immunocompromised patients, have yielded conflicting results.<sup>4,14,15</sup> Furthermore, the
generalizability of these trials, particularly to undifferentiated hypoxemic respiratory
failure in the emergency department, is limited given patients often require initiation of
respiratory support before a clinical diagnosis can be made.

66

Additionally, many of the primary outcomes used in trials of non-invasive respiratory 67 68 support, such as intubation and ventilator-free days, hinge on subjective practice decisions that limit their interpretation.<sup>16</sup> Composite outcomes can help overcome the 69 70 limitations of potentially subjective individual endpoints. However, traditional approaches to generating composite outcomes lead to loss of the relative importance of 71 72 key variables (e.g., mortality and need for intubation are treated similarly) and have 73 statistical limitations that prevent the combination of different types of variables (e.g., binary mortality and continuous ventilator-free days). The Win Ratio, which has been 74 broadly applied in cardiology trials, offers a novel approach to composite outcomes, 75 allowing the combination of different types of variables ranked by clinical relevance.<sup>17</sup> 76 77 The goal of this study was to compare the effectiveness of initial treatment of acute 78 hypoxemic respiratory failure with HFNC versus NIV on a composite outcome of major 79 adverse pulmonary events, calculated using a Win Ratio.

80

#### 81 Materials and Methods

82 Study design and setting

It is made available under a CC-BY-NC-ND 4.0 International license .

83 This is a single-center, propensity score matched, retrospective cohort study comparing

84 initial treatment with HFNC vs NIV in patients with acute hypoxemic respiratory failure.

85 This study was approved by the University of Michigan (UM) Institutional Review Board

on 3/14/2023 (HUM00232776) as a secondary data use, exempt study.

87

88 Data Source

89 We extracted data from the electronic health record (EPIC, Epic systems, Verona,

90 Wisconsin) via queries to our health system's data warehouses (Clarity and Caboodle)

and, for respiratory support mode data, directly from clinical flowsheets. Each variable

used in our analysis, its definition and source are listed in **eTable 1**. There were no

missing data for the exposure or outcome variables. Encounters with missing data on

94 covariates in the propensity score model were excluded.

95

## 96 Inclusion and Exclusion Criteria

We included patients  $\geq$ 18 years-old presenting to the University of Michigan adult 97 emergency department (ED) between 1/2018-12/2022 who received HFNC or NIV 98 99 within 24 hours of ED arrival. To capture acute respiratory failure, we excluded patients who were on chronic home ventilator support, had a tracheostomy, or received non-100 101 invasive respiratory support only after extubation. We also excluded patients who had 102 positive SARS-CoV-2 antigen test and clinically suspected COVID-19 infection. At our institution, HFNC was the predominant respiratory support mode used for patients with 103 104 COVID-19 based on concerns about aerosolization and virus transmission with NIV. A

It is made available under a CC-BY-NC-ND 4.0 International license .

- single patient may have had multiple encounters during the study period; each
- 106 encounter was considered an individual observation.
- 107
- 108 Data collection and definition of respiratory support mode

109 We identified patients who received HFNC or NIV within 24 hours of presentation to the 110 ED based on clinical flowsheets. At our institution, respiratory therapists and nurses record respiratory support mode and settings in a flowsheet at least once per hour and 111 112 whenever mode or setting changes are made. We defined HFNC as any delivery of 113 greater than 20 liters/minute oxygen from a heated, humidified oxygen system. We defined NIV as any non-invasive ventilation mode (continuous positive airway pressure 114 115 or bilevel positive airway pressure). We classified patients who received more than one 116 non-invasive respiratory support mode during a given hour according to the dominant mode (mode used most frequently) for the hour. For the primary analysis, we classified 117 patients as receiving initial HFNC or NIV if they received those modes exclusively for 118 119 the first two hours after initiation, to ensure stable initial group assignment.

120

#### 121 Study Outcomes

The primary outcome was a hierarchical composite outcome of major adverse pulmonary events: 28-day mortality, 28-day ventilator-free days, and hours spent on non-invasive respiratory support from initiation through hour 72. The primary outcome was calculated using a Win Ratio (see *Data Analysis* below for details). We also evaluated the components of the composite major adverse pulmonary events outcome

It is made available under a CC-BY-NC-ND 4.0 International license .

individually: mortality and time to death (28-day and in-hospital), intubation rate,

128 ventilator-free days, and non-invasive respiratory support hours.

129

130 Data Analysis

131 We used a logistic regression model to calculate a propensity score for the odds of

132 receiving NIV using pre-specified patient characteristics typically available at the time of

initiation of HFNC or NIV: age, sex, body mass index, Charlson comorbidity index,

history of congestive heart failure, chronic obstructive pulmonary disease (COPD), or

obstructive sleep apnea, comparison of measured pCO<sub>2</sub> by blood gas (venous or

arterial) to expected pCO<sub>2</sub> by Winter's formula, time from ED arrival to HFNC or NIV

initiation, initial lactate, initial Glasgow Coma Score, and highest day 1 sequential organ

failure assessment (SOFA) score. While SOFA score is not available on ED arrival, it

139 was included in the propensity score model because it provides a surrogate measure for

140 severity of illness. ICD-10 diagnosis codes were recorded to understand etiologies of

141 respiratory failure but were not included in the propensity score model, as discharge-

142 level diagnoses are not available at the time of HFNC or NIV initiation.

143

Using the propensity score, we matched patients 1:1 utilizing greedy nearest neighbor matching with calipers set at 0.2 standard deviations.<sup>18</sup> We used standard descriptive statistics, including standard mean differences (SMD) and Kolmogorov-Smirnov statistcs, to assess for covariate balance and distribution before and after propensityscore matching. SMD < 0.1 after matching was considered acceptable balance.</p>

149

It is made available under a CC-BY-NC-ND 4.0 International license .

150 To calculate the primary outcome of major pulmonary adverse events, we used a Win Ratio, a statistical method for combining variables into a hierarichal composite outcome. 151 Unlike typical composite outcomes that assign similar weight to outcomes regardless of 152 their severity (i.e., including both all-cause mortality and need for repeat intervention) or 153 154 take an "all-or-nothing" approach to evaluating the presence vs absence of an event, 155 the Win Ratio accommodates mixed variable types (e.g., binary, ordinal, continuous, time-to-event) and ranks variables by clinical relevance and patient priorities. Prior 156 literature has defined the calculation of the Win Ratio in detail.<sup>17</sup> In brief, we generated 157 158 all possible pairs of patients on NIV and HFNC. Pairs were sequentially compared on outcomes based on pre-determined importance: 1) 28-day mortality as a survival event, 159 160 2) 28-day ventilator-free days, and 3) non-invasive respiratory support hours from 161 initiation to hour 72. We incorporated selective tie-breaking to best parallel clinical 162 reasoning. For example, for two individuals who tied on mortality, we did not compare ventilator-free days or non-invasive respiratory support hours. Total wins and losses 163 were added up across all three outcome tiers and compared to generate the Win Ratio, 164 which was calculated using the WinRatio package (v1.0).<sup>19</sup> 165

166

Individual secondary outcomes were compared using Mann-Whitney U tests for
continuous variables and Chi-squared tests for categorical variables. Time to death and
time to intubation were analyzed using a Kaplan-Meier survival analysis. Hourly
respiratory support mode and daily patient status were visualized using stacked
histogram plots.

172

It is made available under a CC-BY-NC-ND 4.0 International license .

We conducted several sensitivity analyses: 1) intention-to-treat framework: inclusion of

173

patients who crossed-over between respiratory support modes or had discontinuation of 174 non-invasive respiratory support in the first 2 hours, 2) alternative approaches to 175 calculating the Win Ratio. 176 177 178 Initial data cleaning, data exploration, and visualization was performed using Tableau (Tableau Software). Final data cleaning and all statistical analyses were performed 179 180 using R (v4.2.1) in R Studio (v2022.2.3). 181 Results 182 Between January 2018 and December 2022, 2,208/361,459 (0.6%) adult ED 183 encounters required non-invasive respiratory support within 24 hours of ED arrival. Of 184 these, 1,265/2,208 (57.3%) met study inclusion criteria (Figure 1). HFNC was the 185 predominant mode, used in 795/1,265 (62.8%) encounters. Patients treated with NIV 186 187 and HFNC had large differences in baseline congestive heart failure (78.3% vs 54.5%, SMD 0.52), pCO<sub>2</sub> above expected based on Winter's Formula (67.7% vs 33.7%, SMD 188 189 0.74), shock index (heart rate/systolic blood pressure: 0.7 vs 0.8, SMD 0.36) and lactate >4 mmol/L (9.8% vs 15.0%, SMD 0.22) (Table 1). The most common encounter 190 diagnosis codes were respiratory failure not otherwise specified (89.7% vs 85.5%), 191 192 followed by volume overload (54.1%) and pneumonia (48.9%) in the HFNC group and volume overload (78.1%) and COPD/asthma exacerbation (52.3%) in NIV group 193 194 (eTable 2). 195

It is made available under a CC-BY-NC-ND 4.0 International license .

196	In our propensity model, ( <b>eFigure 1</b> ) body mass index (Odds Ratio (OR) 1.03 [per kg/m <sup>2</sup>
197	increase], 95%CI: 1.02-1.05), history of congestive heart failure (OR 2.29, 95%CI: 1.70-
198	3.11), and pCO2 above expected by Winter's formula (OR 3.49, 95%CI: 2.48-4.96)
199	were associated with increased odds of treatment with NIV, while hemodynamic
200	instability (shock index: OR 0.46 [per unit increase], 95%CI: 0.26-0.82) and higher
201	SOFA (OR 0.91 [per point increase], 95%CI: 0.86-0.96) were associated with lower
202	odds of receiving NIV.
203	
204	We matched 736/1,265 (58.1%) eligible patients at a ratio of 1:1, including 368/795
205	(45.9%) on HFNC and 368/470 (78.3%) on NIV. Patient characteristics were well-
206	balanced between groups after matching, with all SMDs <0.1 except body mass index
207	(SMD 0.109) (Table 1, eFigure 2). Matched NIV patients were similar to overall NIV
208	patients, while matched HFNC patients had higher rates of congestive heart failure,
209	higher body mass index, and more $pCO_2$ above expected by Winter's formula than
210	overall HFNC patients ( <b>Table 1</b> ).
211	

212 The primary outcome was major adverse pulmonary events. We first evaluated

individual components of the major adverse pulmonary events outcome (Table 2).

214 There was no difference between patients treated with NIV vs HFNC in 28-day mortality

215 (17.7% vs 23.1%, p=0.08) or ventilator-free days (median [IQR]: 28 [25,28] vs 28 [13,

216 28], p=0.50). However, patients treated with NIV spent significantly fewer hours on non-

invasive respiratory support within the first 72 hours of initiation (median 7 vs 13 hours,

p<0.001). Hourly respiratory support modes up to 72 hours post-HFNC or NIV initiation

It is made available under a CC-BY-NC-ND 4.0 International license .

- and daily patient status out to 28 days by treatment group are presented in the
- supplement (**eFigure 3 and 4**). Time to death by 28 days was also similar between
- 221 patients treated with NIV vs HFNC (**eFigure 5**).
- 222
- 223 We then calculated the composite major adverse pulmonary events using the Win
- Ratio. There were 135,424 potential matched patient pairs (368x368). In total, NIV won
- in 74,008 (54.6%) pairs while HFNC won in 58,957 (43.5%), resulting in a Win Ratio for
- 226 NIV of 1.26 (95% CI: 1.06-1.49, p=0.009). NIV won over HFNC for 28-day mortality
- 227 (wins, as percent of all pairs: 20.8% vs 15.8%) and NIRS hours (wins: 23.7% vs 14.7%),

but not ventilator-free days (wins: 10.1% vs 13.0%). Only 2,459 (1.8%) pairs tied on all

tiers (Table 2, Figure 2) Results were robust to sensitivity analyses including patients

- with early respiratory mode cross-over and discontinuation (**eTable 3**) and alternative
- approaches to Win Ratio calculation (**eTable 4**).
- 232

## 233 Discussion

In this propensity matched retrospective study of patients with acute hypoxemic
respiratory failure, initial treatment with NIV decreased time spent on non-invasive
respiratory support in the first 72 hours but did not have a significant impact on
individual outcomes of mortality or ventilator-free days. However, treatment with NIV
was associated with lower composite major adverse pulmonary events, calculated using
a Win Ratio.

240

It is made available under a CC-BY-NC-ND 4.0 International license .

241 Our finding that initial treatment with NIV may decrease overall major adverse pulmonary events compared to HFNC contrasts with the findings of the prominent 242 FLORALI trial. In that trial, HFNC improved mortality and ventilator-free days compared 243 244 to NIV.<sup>13</sup> Unfortunately, the results of the FLORALI trial have not been replicated 245 consistently in the few other trials that have have compared HFNC and NIV in acute hypoxemic respiratory failure.<sup>3,4,14,15,20</sup> The failure to replicate these results may be due 246 to limitations of the FLORALI trial (small sample size with potentially high fragility index) 247 and/or due to differences in patient populations enrolled across studies. For example, 248 249 while our study included all patients receiving HFNC or NIV within 24 hours of ED 250 arrival, the FLORALI trial enrolled a much narrower population of ICU patients with pure 251 hypoxemic respiratory failure, excluding patients with hypercarbia, cardiogenic pulmonary edema, or COPD exacerbations.<sup>13</sup> HFNC and NIV have not been directly 252 compared in these other conditions (i.e., heart failure and COPD exacerbations), where 253 recommendations to use NIV are based on comparisons of NIV to low-flow oxygen not 254 255 HFNC.3,11

256

There has only been one trial comparing HFNC vs NIV in a broad population of
patients.<sup>12</sup> Similar to our study, that trial by Doshi *et al* enrolled ED patients with acute
hypoxemic respiratory failure and found HFNC was non-inferior to NIV based on
intubation rates, though the trial was small and not powered to assess other outcomes.
Therefore, the optimal non-invasive respiratory support mode for treating early,
undifferentiated hypoxemic respiratory failure remains unclear. Our results add to
clinical equipoise by suggesting that initial use of NIV may improve outcomes compared

It is made available under a CC-BY-NC-ND 4.0 International license .

to HFNC in the broader population of patients with early, undifferentiated hypoxemic
 respiratory failure.

266

Understanding the optimal initial treatment for undifferentiated hypoxemic respiratory 267 268 failure is critical, particularly in the ED, where the choice between HFNC and NIV often 269 must be made before information about a patient's diagnosis is fully available. Indeed, our findings suggest that in practice patients frequently have multiple risk factors for 270 respiratory failure. For example, even among the patients who received HFNC, over half 271 272 had a documented history of heart failure and/or COPD. While the frequency of these comorbidities may be high due to our institution's role as a tertiary referral center, this 273 274 finding suggests that it may be challenging to identify patients with specific etiologies of 275 respiratory failure in real time. This is further reflected by the mix of encounter diagnosis codes in our cohort, which suggest many patients had mixed etiologies of respiratory 276 277 failure.

278

Our results underscore the need for a randomized controlled trial to further understand 279 280 the impact of NIV vs HFNC in patients with early, undifferentiated hypoxemic respiratory failure. In order to best inform practice decisions, such trials must employ novel design 281 approaches, such as exemption from informed consent and pragmatic designs<sup>21</sup>, to 282 283 capture patients early in their disease course, ideally in the ED at the time of NIV or HFNC initiation. Future clinical trials must also select appropriate outcomes to 284 285 overcome the limitations of potentially subjective primary outcomes, such as intubation 286 or ventilator-free days.

It is made available under a CC-BY-NC-ND 4.0 International license .

287

Our study suggests that use of a Win Ratio may be a feasible approach to using 288 composite outcomes in future studies of respiratory support modes. In our study, 289 calculating the composite outcome of major adverse pulmonary events using a Win 290 291 Ratio allowed a more nuanced understanding of the impact of NIV and HFNC on patient 292 outcomes than individual outcomes alone. At the individual outcome level, we found no 293 association between respiratory support mode and mortality or ventilator-free days. In contrast, based on the composite outcome of major adverse pulmonary events 294 295 calculated using a Win Ratio, NIV was superior to HFNC overall and at the mortality and 296 respiratory support hour tiers. These findings highlight one challenge of studies of 297 respiratory failure: the limitations of single outcomes such as mortality or intubation, 298 which can obscure other clinically important outcomes particularly when only a subset of 299 patients experience death or intubation. For example, in our study, a majority of patients 300 survived and were never intubated, but patients treated initially with NIV spent less total 301 time on non-invasive respiratory support. Given both HFNC and NIV require ICU level support at many institutions, spending less time on these devices is a potentially 302 303 important outcome in patients who survive and are not intubated. Additionally, decisions about intubation and extubation are often subjective<sup>16</sup>, limiting the utility of intubation 304 305 and ventilator-free days as primary outcomes. The Win Ratio offers a mechanism to 306 compare multiple relevant patient outcomes, while maintaining a hierarchical approach that reflects the relative importance of outcomes to patients and their families: first 307 308 comparing mortality, then ventilator-free days, then non-invasive respiratory support

It is made available under a CC-BY-NC-ND 4.0 International license .

309 hours. Our results suggest that a similar Win Ratio could be used as a primary outcome

- 310 for future clinical trials comparing respiratory support modalities.
- 311

312 Limitations

313 This study has several limitations common to retrospective studies. First, there is a risk 314 that our findings are the result of residual confounding. The use of propensity score matching limits that risk, but the presence of confounding on unmeasured variables 315 remains possible and a prospective clinical trial is needed to verify these findings. 316 317 Secondly, the assignment of the exposure group required that patients receive HFNC or NIV exclusively for the first two hours after initiation, which may limit generalizability to 318 319 patients who switch support modalities or discontinue them within the first two hours. 320 However, in sensitivity analyses where the exposure group was assigned by first modality, a similar result was observed. Finally, as a single-center study performed at a 321 tertiary care hospital, generalizability may be limited as practice patterns regarding 322 323 HFNC and NIV use may differ at other centers. While indications for HFNC and NIV selection may vary across institutions, propensity matching helps ensure that the 324 325 patients included in our study were similar and might be candidates for either HFNC or 326 NIV more broadly.

327

## 328 Conclusion

In this propensity matched retrospective study of patients with early acute hypoxemic
respiratory failure, initial treatment with NIV was superior to HFNC for major adverse
pulmonary events, calculated using a Win Ratio. These results underscore the need for

It is made available under a CC-BY-NC-ND 4.0 International license .

- 332 novel randomized controlled trials to definitively determine the merits of each non-
- 333 invasive respiratory support strategy.

It is made available under a CC-BY-NC-ND 4.0 International license .

## Acknowledgements

This material is the result of work supported with resources and the use of facilities at the Ann Arbor VA Medical Center.

It is made available under a CC-BY-NC-ND 4.0 International license .

## References

- 1. Behrendt CE. Acute Respiratory Failure in the United States. *Chest.* 2000;118(4):1100-1105. doi:10.1378/chest.118.4.1100
- Kempker JA, Abril MK, Chen Y, Kramer MR, Waller LA, Martin GS. The Epidemiology of Respiratory Failure in the United States 2002–2017: A Serial Cross-Sectional Study. *Crit Care Explor*. 2020;2(6):e0128. doi:10.1097/CCE.00000000000128
- Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. *Intensive Care Med.* Published online June 16, 2023. doi:10.1007/s00134-023-07050-7
- Nair PR, Haritha D, Behera S, et al. Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia. *Respir Care*. 2021;66(12):1824-1830. doi:10.4187/respcare.09130
- Al Hashim AH, Al Reesi A, Al Lawati NM, et al. Comparison of Noninvasive Mechanical Ventilation With High-Flow Nasal Cannula, Face-Mask, and Helmet in Hypoxemic Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial. *Crit Care Med*. 2023;Publish Ahead of Print. doi:10.1097/CCM.00000000005963
- Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on noninvasive support. *Minerva Anestesiol*. 2019;85(9). doi:10.23736/S0375-9393.19.13418-9
- Carteaux G, Parfait M, Combet M, Haudebourg AF, Tuffet S, Mekontso Dessap A. Patient-Self Inflicted Lung Injury: A Practical Review. *J Clin Med.* 2021;10(12):2738. doi:10.3390/jcm10122738
- 8. Sun J, Li Y, Ling B, et al. High flow nasal cannula oxygen therapy versus noninvasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. *Int J Chron Obstruct Pulmon Dis*. 2019;Volume 14:1229-1237. doi:10.2147/COPD.S206567
- Mauri T, Turrini C, Eronia N, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. *Am J Respir Crit Care Med*. 2017;195(9):1207-1215. doi:10.1164/rccm.201605-0916OC
- 10. Nishimura M. High-Flow Nasal Cannula Oxygen Therapy Devices. *Respir Care*. 2019;64(6):735-742. doi:10.4187/respcare.06718

- 11. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016
- 12. Doshi P, Whittle JS, Bublewicz M, et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. *Ann Emerg Med.* 2018;72(1):73-83.e5. doi:10.1016/j.annemergmed.2017.12.006
- Frat JP, Thille AW, Mercat A, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. *N Engl J Med*. 2015;372(23):2185-2196. doi:10.1056/NEJMoa1503326
- Coudroy R, Frat JP, Ehrmann S, et al. High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial. *Lancet Respir Med*. 2022;10(7):641-649. doi:10.1016/S2213-2600(22)00096-0
- 15. Grieco DL, Menga LS, Cesarano M, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021;325(17):1731. doi:10.1001/jama.2021.4682
- Yarnell CJ, Johnson A, Dam T, et al. Do Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure Exist? A Cohort Study. *Am J Respir Crit Care Med*. 2023;207(3):271-282. doi:10.1164/rccm.202206-1092OC
- 17. Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. *Eur Heart J*. 2020;41(46):4391-4399. doi:10.1093/eurheartj/ehaa665
- Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivar Behav Res.* 2011;46(3):399-424. doi:10.1080/00273171.2011.568786
- 19. Git Hub, Inc. Win Ratio Applications. Published 2023. Accessed August 15, 2023. https://github.com/CRF-Biostatistics/WinRatioApplications
- Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. *JAMA*. 2022;327(6):546. doi:10.1001/jama.2022.0028
- 21. Casey JD, Beskow LM, Brown J, et al. Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. *Lancet Respir Med*. 2022;10(7):700-714. doi:10.1016/S2213-2600(22)00044-3

It is made available under a CC-BY-NC-ND 4.0 International license .

#### Figure 1. Study Flow Diagram



<sup>2</sup>Chronic assisted ventilation based on vent mode, respiratory therapy documentation, or ICD-10 <sup>3</sup>Patients received NIRS after extubation within 24 hours of ED arrival <sup>4</sup>Recent Covid-19 PCR positive and clinically considered positive

<sup>5</sup>Any crossover between HFNC and NIV within 2 hours of initiation

**Figure 1 Legend:** Study flow diagram. The primary analysis included N=1,265 patients in the pool for matching. A sensitivity analysis was performed for all patients receiving qualifying non-invasive respiratory support (NIRS), including early cross-over and discontinuation (N=1,615, see eTable 1). <u>Definitions</u>: ED= Emergency Department, O2= oxygen, L= liter, NIRS= non-invasive respiratory support, which includes both high-flow nasal cannula and non-invasive ventilation, vent= ventilation, HFNC= high-flow nasal canula, NIV= non-invasive ventilation, which includes continuous positive airway pressure and bilevel positive airway pressure.

It is made available under a CC-BY-NC-ND 4.0 International license .

# Figure 2. Visualization of the Win Ratio of Major Adverse Pulmonary Events



**Figure 2 Legend.** Comparison of Major Pulmonary Adverse Events between NIV and HFNC using the Win Ratio. The Win Ratio is the ratio of overall "wins for NIV" over "wins for HFNC." A positive Win Ratio suggests NIV results in a better composite outcome compared to HFNC. Percentages represent the percent of pairs out of the total possible pairs. On tier 1 (time to death) and overall, the percentages sum to 100% because all patient pairs are compared at these levels. However, tiers 2 and 3 only compare patients who tied on the previous tier. For example, in tier 2 (ventilator-free days), the percentages add to the number of patients who tied on the previous tier (63.3%).

<u>Definitions</u>: Non-invasive respiratory support hours = time spent on non-invasive respiratory support (NIV or HFNC) in hours, from initiation through hour 72. NIV= non-invasive ventilation. HFNC= high-flow nasal cannula.

Table 1. Baseline patient characteristics before and after propensity score matching								
	Ov	verall Cohort		Matched Cohort				
	<b>HFNC</b> (n=795)	<b>NIV</b> (n=470)	SMD	<b>HFNC</b> (n = 368)	<b>NIV</b> (n = 368)	SMD		
Age, year	66.7 [55.4, 75.7]	68.9 [59.6, 77.6]	0.218	69.4 [57.1, 78.2]	68.3 [59.0, 77.6]	0.031		
Male sex	466 (58.6)	245 (52.1)	0.131	194 (52.7)	199 (54.1)	0.027		
Body Mass Index, kg/m2	26.3 [22.1, 31.2]	29.0 [23.6, 35.5]	0.395	27.4 [23.1, 32.9]	27.5 [23.0, 34.3]	0.109		
Charlson Comorbidity Index	8.0 [4.0, 14.0]	9.0 [5.0, 14.0]	0.154	8.0 [4.0, 14.0]	8.5 [5.0, 14.0]	0.047		
Individual comorbidities at baseline								
Congestive heart failure	433 (54.5)	368 (78.3)	0.521	264 (71.7)	266 (72.3)	0.012		
Chronic obstructive pulmonary disease	482 (60.6)	326 (69.4)	0.184	246 (66.8)	246 (66.8)	<0.001		
Obstructive sleep apnea	160 (20.1)	132 (28.1)	0.187	86 (23.4)	96 (26.1)	0.063		
Expected pCO <sub>2</sub> *								
pCO <sub>2</sub> at expected	184 (23.1)	70 (14.9)		70 (19.0)	68 (18.5)			
pCO <sub>2</sub> above expected	268 (33.7)	318 (67.7)	0.74	207 (56.2)	218 (59.2)	0.065		
pCO <sub>2</sub> below expected	343 (43.1)	82 (17.4)		91 (24.7)	82 (22.3)			
First hours of non-invasive respiratory support	2.0 [1.0, 7.0]	2.0 [1.0, 4.8]	0.272	2.0 [1.0, 5.0]	2.0 [1.0, 5.0]	0.026		
Systolic shock index	0.8 [0.7, 1.0]	0.7 [0.5, 0.9]	0.362	0.7 [0.6, 0.9]	0.7 [0.6, 0.9]	0.020		
Lactate group, n(%)								
< 2 mmol/L	415 (52.2)	293 (62.3)		210 (57.1)	220 (59.8)			
2-4 mmol/L	261 (32.8)	131 (27.9)	0.22	102 (29.6)	104 (28.3)	0.058		
>4 mmol/L	119 (15.0)	46 (9.8)		49 (13.3)	44 (12.0)			
Glasgow Coma Score	15 [15, 15]	15 [15, 15]	0.106	15 [15, 15]	15 [15, 15]	0.095		
Highest Day 1 SOFA	5.0 [4.0, 7.0]	5.0 [3.0, 6.0]	0.275	5.0 [4.0, 6.0]	5.0 [4.0, 7.0]	0.016		

**Table 1 Legend:** Baseline characteristics in the overall cohort and matched study cohort. Data are presented as median [IQR] and N(%). \*Expected pCO<sub>2</sub> was calculated using the first available bicarbonate from a basic metabolic panel and pCO<sub>2</sub> from the first arterial or venous blood gas, comparing actual pCO<sub>2</sub> to pCO<sub>2</sub> that would be expected based on Winter's formula. pCO<sub>2</sub> above expected suggests superimposed respiratory alkalosis, while pCO<sub>2</sub> below expected suggests superimposed respiratory acidosis. Patients were matched on calculated expected pCO<sub>2</sub>, not individual pH, pCO<sub>2</sub>, or bicarbonate values.

<u>Definitions</u>: HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation, SMD= standard mean difference, systolic shock index= ratio of heart rate / blood pressure, SOFA= sequential organ failure assessment. Non-invasive respiratory support refers to both HFNC and NIV.

Table 2. Individual outcomes for patients receiving HFNC vs NIV in the overall and matched cohort								
	Ove	erall Cohort	Matched					
	<b>HFNC</b> (n=795)	<b>NIV</b> (n=470)	p- value	<b>HFNC</b> (n = 368)	<b>NIV</b> (n = 368)	p- value		
28-day mortality, n (%)	215 (27.0)	74 (15.7)	<0.001	85 (23.1)	65 (17.7)	0.082		
Time to death in 28-days, median days [IQR]	6.8 [3.1, 14.2]	6.2 [2.7, 13.0]	0.539	7.2 [3.1, 16.2]	6.1 [2.7, 12.9]	0.280		
In-hospital mortality, n (%)	169 (21.3)	58 (12.3)	<0.001	64 (17.4)	51 (13.9)	0.223		
Time to death in hospital, median days [IQR]	5.2 [2.4, 12.5]	4.2 [2.2, 8.9]	0.415	5.5 [2.5, 13.6]	4.0 [2.2, 9.5]	0.406		
Intubation within 72 hours of HFNC or NIV initiation, n (%)	160 (20.1)	68 (14.5)	0.014	57 (15.5)	57 (15.5)	1.00		
Ventilator-free days, median [IQR]	28.0 [0.0, 28.0]	28.0 [26.0, 28.0]	<0.001	28.0 [12.8, 28.0]	28.0 [25.0, 28.0]	0.497		
Non-invasive respiratory support hours, median [IQR]	14.0 [6.0, 34.0]	8.0 [4.0, 26.3]	<0.001	13.0 [6.0, 33.0]	7.0 [4.0, 14.0]	<0.001		

**Table 2 Legend.** Individual patient outcomes before and after propensity score matching. Data are presented as n(%) and median [IQR]. p-values were calculated using Mann-Whitney U for continuous variables and Chi-squared test for categorical variables. Grey rows represent outcomes that contribute to the primary composite Major Adverse Pulmonary Events outcome. Ventilator-free days were calculated from admission through day 28. Non-invasive respiratory support hours were hours spent on HFNC or NIV calculated from initiation through hour 72.

<u>Definitions:</u> HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation.

Table 3. Win Ratio of composite Major Adverse Pulmonary Events for patients receiving HFNC vs NIV								
		C	Overall Cohor	t	Matched Cohort			
Tier	Outcome	NIV wins	HFNC wins	Ties	NIV wins	HFNC wins	Ties	
		92,713	51,255	229,682	28,232	21,442	85,750	
1	Time to death (28-day mortality)	(24.8%)	(13.7%)	(61.5%)	(20.8%)	(15.8%)	(63.3%)	
		45,921	42,225	141,536	13,615	17,589	54,546	
2	Ventilator-free days	(12.3%)	(11.3%)	(37.9%)	(10.0%)	(13.0%)	(40.2%)	
		87,343	48,011	6,182	32,161	19,926	2,459	
3	Non-invasive respiratory support hours	(23.4%)	(12.8%)	(1.7%)	(23.7%)	(14.7%)	(1.8%)	
		225,977	141,491	6,182	74,008	58,957	2,459	
	Totals, by category	(60.5%)	(37.9%)	(1.7%)	(54.6%)	(43.5%)	(1.8%)	
	Total possible pairs	373,650			135,424			
	Win Ratio (95% CI), p-value	1.60 (1.39- 1.83), p <0.001			1.26 (1.06 -1.49), p=0.009			

**Table 3 Legend.** Details of the Win Ratio used to calculate the composite Major Adverse Pulmonary Events in the overall cohort (N=1,265) and in the matched study cohort (N=736). The Win Ratio in the matched cohort is the primary outcome, which is also displayed visually in Figure 2.

The Win Ratio is the ratio of overall "wins for NIV" over "wins for HFNC." A positive Win Ratio suggests NIV results in a better composite outcome compared to HFNC. Percentages represent the percent of pairs out of the total possible pairs. On tier 1 (time to death) and overall, the percentages sum to 100% because all patient pairs are compared at these levels. However, tiers 2 and 3 only compare patients who tied on the previous tier. For example, in tier 2 (ventilator-free days), the percentages add to the number of patients who tied on the previous tier.

<u>Definitions:</u> HFNC= high flow nasal cannula, NIV= non-invasive positive pressure ventilation. Ventilator-free days were calculated from admission through day 28. Non-invasive respiratory support hours were hours spent on HFNC or NIV calculated from initiation through hour 72.